It's time for the Lightning Round. Cramer makes the call on viewer favorites.» Read More
NEW YORK, Nov 22- U.S. stocks rose on Friday, led by healthcare stocks, putting the Dow and S&P 500 on track for a seventh straight week of gains. Shares of Biogen shot up 11.9 percent on heavy volume to $282.37 after the company won 10 years of exclusivity protection for its multiple sclerosis drug, Tecfidera, from regulators in Europe.
NEW YORK, Nov 22- U.S. stocks edged higher on Friday in the absence of economic data and ahead of a holiday-shortened week in the United States, a day after the Dow industrials closed above 16,000 for the first time.
Friday's midday movers.
NEW YORK, Nov 22- U.S. stocks were little changed on Friday amid a dearth of data and ahead of a holiday-shortened week in the United States, a day after the Dow industrials broke 16,000 for the first time.
*Biogen says now ready to launch oral medicine in Europe. LONDON, Nov 22- Biogen Idec has won 10 years of regulatory exclusivity for its top-selling multiple sclerosis drug Tecfidera in Europe, paving the way for its launch in markets that could account for a large chunk of future sales.
*Time Warner Cable up as Charter nears bank deal for bid. NEW YORK, Nov 22- U.S. stocks were set to tick up at the open on Friday after the Dow industrials closed above 16,000 for the first time, amid a dearth of data and ahead of a holiday-shortened week in the United States.
LONDON, Nov 22- Biogen Idec has won regulatory protection for its top-selling multiple sclerosis drug Tecfidera in Europe, paving the way for its launch in markets that could account for a large proportion of future sales.
Health-care stocks are surging amid the confusion of Obamacare. Apparently, investors don't see the current morass as problematic at all.
SILVER SPRING, Maryland, Nov 13- A federal advisory panel said safety issues do not preclude approval of Sanofi SA's experimental multiple sclerosis drug Lemtrada on Wednesday, but voiced concerns about the quality of clinical studies.
SILVER SPRING, Nov 13- A federal advisory panel recommended approval of Sanofi SA's experimental multiple sclerosis drug Lemtrada on Wednesday, but said the drug should be reserved for patients who have failed other therapies. Nathan Fountain of the University of Virginia School of Medicine and the panel's chairperson.
Gazyva, previously known as GA101, was approved in the United States last week as an initial treatment for patients with chronic lymphocytic leukemia, or CLL, one of the most common forms of blood cancer. It is awaiting approval decisions in Europe and other markets.
*Ariad says working with FDA to find a way to bring drug back. WASHINGTON, Oct 31- Ariad Pharmaceuticals Inc has suspended sales of its leukemia drug Iclusig after an investigation by the U.S. Food and Drug Administration found that a significant number of patients developed life-threatening blood clots or narrowing of the veins.
*Apple shares edge up ahead of results. NEW YORK, Oct 28- The S&P 500 closed at another record high on Monday as expectations were high that the Federal Reserve will keep its stimulus in place when it meets this week.
*Apple shares edge up ahead of results. NEW YORK, Oct 28- U.S. stocks edged higher on Monday, pushing the S&P 500 to another intraday high, with expectations high the Federal Reserve will keep its stimulus in place for the time being.
NEW YORK, Oct 28- U.S. stocks were little changed on Monday as investors found few catalysts to push equities higher after the S&P 500' s latest record high.
Take a look at some of Monday's midday movers:
Oct 28- Biogen Idec Inc on Monday reported $286 million in third-quarter sales of its high-profile new multiple sclerosis drug Tecfidera, providing fresh evidence that the medicine is off to an impressive launch and exceeding all expectations.
NEW YORK, Oct 28- U.S. stocks were little change on Monday as investors found few reasons to keep pushing shares higher after the S&P 500 climbed to a series of records on expectations for continuing Federal Reserve stimulus.
As earnings season hits halftime, there are three themes emerging.
Editor: Malcolm Davidson +44 20 7542 6958 Global Picture Desk:+ 65 6870 3775 Global Graphics Desk:+ 65 6870 3595. FRANKFURT- Down in the undergrowth of Europe's economy, something is stirring. Bankia's turnaround mirrors Spain's hesitant recovery.